Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMgc Pharma Ltd Regulatory News (MXC)

Share Price Information for Mgc Pharma Ltd (MXC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.00
Bid: 21.00
Ask: 23.00
Change: 0.00 (0.00%)
Spread: 2.00 (9.524%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.00
MXC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Application for Admission to Trading

25 Apr 2022 11:08

RNS Number : 2172J
MGC Pharmaceuticals Limited
25 April 2022
 

 

MGC Pharmaceuticals Ltd.

Compliance Release - Application for Admission to Trading

25 April 2022

ASX, LSE: MXC

 

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that it is applying for the admission to the Financial Conduct Authority's Official List, and to trading on the Main Market of the LSE for the following Fully Paid Ordinary Shares (Shares) recently issued by MGC Pharma, with the Company seeking admission to trading for these Shares from 8:00am (GMT) on Thursday 28 April 2022.

The Company advises that the details of the 900,000 Shares for which these applications are being lodged are as follows:

· 900,000 Shares issued on the exercise of securities granted under the Company's Employee Share Scheme

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBGGDSLGDDGDU
Date   Source Headline
28th Mar 20249:12 amRNSPDMR Notification
28th Mar 20249:07 amRNSRefinancing of Convertible Securities Agreement
18th Mar 20248:23 amRNSResults of General Meeting
29th Feb 20249:36 amRNSHalf-year Report
19th Feb 20244:00 pmRNSUpdate - Application for Admission to Trading
13th Feb 202410:00 amRNSDispatch of General Meeting Documents
31st Jan 20247:30 amRNSDecember 2023 Quarter Activity Report
11th Jan 20249:54 amRNSDirector/PDMR Shareholding
22nd Dec 20239:09 amRNSCompany Update & Placing to Raise US$500,000
19th Dec 20237:57 amRNSArtemiCâ„¢ receives FDA Approval in Saudi Arabia
18th Dec 20239:06 amRNSNon-Deal Roadshow Presentation December 2023
1st Dec 20238:09 amRNSCorporate Update - Board and UK Adviser Changes
30th Nov 20239:08 amRNSResults of Shareholder’s Annual General Meeting
16th Nov 20231:51 pmRNSHolding(s) in Company
13th Nov 20239:15 amRNSHolding(s) in Company
9th Nov 202310:47 amRNSHolding(s) in Company
8th Nov 202311:52 amRNSHolding(s) in Company
8th Nov 202310:00 amRNSCapital Consolidation and US$7.9m Placement
1st Nov 202311:30 amRNSConsolidation and New Fund Raising
1st Nov 202311:03 amRNSMGC Secures US$7.9 Million In Firm Commitments
31st Oct 20239:32 amRNSDispatch of Annual General Meeting Documents
30th Oct 20237:16 amRNSSeptember 2023 Quarter Activity Report
25th Oct 20233:16 pmRNSResults of Shareholder’s General Meeting
9th Oct 202310:02 amRNSDate of AGM & Closing Date of Director Nominations
29th Sep 202310:40 amRNSAnnual Report for the year ended 30 June 2023
26th Sep 20237:36 amRNSLetter From the Managing Director
26th Sep 20237:35 amRNSDispatch of General Meeting Documents
12th Sep 20237:00 amRNSHolding(s) in Company
5th Sep 202312:34 pmRNSResults of Shareholder’s General Meeting
1st Sep 20237:30 amRNSChange of registry address notification
31st Aug 20238:44 amRNS30 June 2023 Preliminary Financial Report
30th Aug 20238:30 amRNSShare Purchase Plan Closed
15th Aug 20237:29 amRNSSPP – Extension of Closing Date
14th Aug 20237:00 amRNSPositive Pre-clinical Trial Results on CimetrA®
4th Aug 20239:10 amRNSDispatch of General Meeting Documents
3rd Aug 20232:23 pmRNSAustralian Prospectus & Share Purchase Plan
2nd Aug 202310:25 amRNSApplication for Admission to Trading
1st Aug 20238:56 amRNSMGC Pharma Launches Share Purchase Plan
31st Jul 20237:00 amRNSPermission for first import of Psilocybin
28th Jul 20239:05 amRNSResignation of Joint Company Secretary
28th Jul 20238:00 amRNSJune 2023 Quarter Activity Report and Cash Flow
21st Jul 202310:56 amRNSHolding(s) in Company
18th Jul 202311:41 amRNSPDMR Notification
14th Jul 20237:00 amRNS£0.7 million Fundraising
12th Jul 20237:00 amRNSFurther re AMC Places another $1M Order of ArtemiC
7th Jul 20237:00 amRNSAMC Places Another US$1M Order of ArtemiC™
3rd Jul 20237:00 amRNSReclassification of Psychedelic Compounds
30th Jun 20239:31 amRNSDetails of Company Address
30th Jun 20239:30 amRNSCompany Update
29th Jun 202310:22 amRNSResults of Shareholder’s General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.